Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Ki vehet részt

• ≥ 18 years old adults at the time of informed consent
• Ability to provide written informed consent and HIPAA authorization
• Biopsy confirmed melanoma
• Eligible for standard of care treatment
• Plan to undergo immunotherapy in neoadjuvant or metastatic setting
• ECOG performance status 0-2
• Anemia defined as hemoglobin < 13 g/dl in addition to ferritin < 100 ng/ml and/or transferrin saturation < 30%

Ki nem vehet részt

• Symptomatic brain metastases that require local treatment (brain metastasis which will be treated with systemic immunotherapy or treated metastasis with without need for steroids for symptomatic management are eligible)
• History of anaphylactic reaction to intravenous iron or any proposed standard of care treatments
• Active infections which in research teams' opinion increases risk for toxicities
• Any condition that in the opinion of PI may interfere with patient being able to complete the required procedures
• Diagnosis of hemoglobinopathies
• Therapeutic Iron supplementation in the past 3 months (oral iron as part of MVI allowed)
• Diagnosis of hemochromatosis
• Pregnant or lactating female adults